Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

Complete response rate (CR)

Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

Time frame: At the end of Cycle 6 (each cycle is 28 days)

Partial response rate (PR)

Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

Time frame: At the end of Cycle 6 (each cycle is 28 days)

Duration of response

Time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with PET-CT.

Time frame: Baseline up to data cut-off (up to approximately 2 years)

2-year progression free survival rate

progression-free survival was defined as the time from the date of first treatment until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.

Time frame: Baseline up to data cut-off (up to approximately 2 years)

2-year overall survival rate

progression-free survival was defined as the time from the date of first treatment until the date of the first documented day of death from any cause.

Time frame: Baseline up to data cut-off (up to approximately 2 years)